Your browser doesn't support javascript.
loading
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.
Grövdal, M; Nahi, H; Gahrton, G; Liwing, J; Waage, A; Abildgaard, N; Pedersen, P T; Hammerstrøm, J; Laaksonen, A; Bazia, P; Terava, V; Ollikainen, H; Silvennoinen, R; Putkonen, M; Anttila, P; Porkka, K; Remes, K.
Afiliação
  • Grövdal M; Department of Medicine, Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Nahi H; Department of Medicine, Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Gahrton G; Department of Medicine, Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Liwing J; Department of Medicine, Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Waage A; 1] Saint Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway [2] KG Jebsen Center for Myeloma Research, IKM, Norwegian University of Science and Technology, Trondheim, Norway.
  • Abildgaard N; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Pedersen PT; Department of Hematology, Esbjerg Hospital, Esbjerg, Denmark.
  • Hammerstrøm J; 1] Saint Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway [2] KG Jebsen Center for Myeloma Research, IKM, Norwegian University of Science and Technology, Trondheim, Norway.
  • Laaksonen A; Department of Hematology, Turku University Hospital, Turku University, Turku, Finland.
  • Bazia P; Department of Hematology, Kainuu Central Hospital, Kajaani, Finland.
  • Terava V; Department of Hematology, Tampere University Hospital, Tampere, Finland.
  • Ollikainen H; Department of Hematology, Satakunta Central Hospital, Pori, Finland.
  • Silvennoinen R; Department of Hematology, Kuopio University Hospital, Kuopio, Finland.
  • Putkonen M; Department of Hematology, Turku University Hospital, Turku University, Turku, Finland.
  • Anttila P; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Porkka K; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Remes K; Department of Hematology, Turku University Hospital, Turku University, Turku, Finland.
Bone Marrow Transplant ; 50(6): 808-12, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25867654
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article